Navigation Links
Valeant Pharmaceuticals Announces Resignation of Michael Van Every From Valeant's Board of Directors
Date:8/18/2011

MISSISSAUGA, Ontario, Aug. 18, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that Michael Van Every has resigned from Valeant's Board of Directors due to health reasons.

"We want to thank Michael for his many years of service to the Company, first at Biovail and then, following the merger of Biovail and Valeant, as part of the new Valeant Board," stated J. Michael Pearson, chairman and chief executive officer.  "Michael's accounting expertise was a tremendous asset to Company and brought a much needed stability to the financial organization during his tenure as Head of the Finance and Audit Committee.  Michael's counsel will be missed and we wish him well in his recovery."

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

(Logo:  http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Valeant Pharmaceuticals Reports 2011 Second Quarter Financial Results
2. Valeant Pharmaceuticals Announces Approval of Sublinox® in Canada
3. Valeant Pharmaceuticals Announces Distribution Agreement for Zuacta™ in Canada
4. Valeant Pharmaceuticals Agrees to Acquire Ortho Dermatologics
5. Sanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc.
6. Valeant Pharmaceuticals Agrees to Acquire Dermik
7. Valeant Pharmaceuticals Announces License Agreement With Meda for North American Rights for Elidel® and Xerese™
8. Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results
9. Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction
10. Valeant Pharmaceuticals to Announce 2011 First Quarter Results on May 9, 2011
11. Valeant Pharmaceuticals Responds to Cephalon Boards Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 18, 2017   Synthetic Biologics, ... company developing therapeutics designed to preserve the microbiome ... today confirmed plans to initiate a Phase 2b/3 ... reformulation of lovastatin lactone designed to reduce methane ... in the gut to treat the underlying cause ...
(Date:1/18/2017)... 18, 2017  Aprima Medical Software, a leading ... management (PM) and revenue cycle management (RCM) solutions ... a former reseller Healthcare Data Solutions (HDS) of ... Aprima will assume full support for HDS,s customers, ... practices across 15 states. Financial terms were not ...
(Date:1/18/2017)... 18, 2017   Spotlight Innovation Inc. ... plans, in the second quarter of 2017, to ... intended to provide relief from chronic pain, is ... It was developed under a licensing agreement with ... derived from snake venom. Additionally, Caretta Therapeutics has ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... 19, 2017 , ... Connecticut Dermatology Group (CDG) is proud and excited to ... dermatologist. Dr. Kim brings an extensive background in cutting-edge dermatology care and research ... to welcome back Dr. Kim to the CDG team” said President and Managing Partner ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Infinity® Massage Chairs ... plan and implement new sales and marketing strategies. Grover comes with a total of ... 5 and a half years as Executive Vice President of Direct Sales at Traeger® ...
(Date:1/18/2017)... ... January 18, 2017 , ... A recent video posting of a ... about the benefits of fidgeting to relieve stress and anxiety. No one was ... Think Ink Pen had just completed a successful Kickstarter campaign raising $67,000 on the ...
(Date:1/18/2017)... ... January 18, 2017 , ... The VA Maryland Health ... on a research project focused on multiple sclerosis (MS). Led by Christopher M. ... to control the disease without compromising normal immune function that often occurs during ...
(Date:1/18/2017)... FL (PRWEB) , ... January 18, 2017 , ... A ... fund raiser for Smile Train, an international charity that provides free surgery to poor ... of mine and in the past I have run to support the efforts of ...
Breaking Medicine News(10 mins):